This approval was based on the findings of an open‐label phase II study, APOLLO, in which the median PFS and ORR of patients with progressed NSCLC harboring EGFR T790M mutation treated with aulmonertinib was 12.3 months and 68.9%. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.